PALLD and pancreatic adenocarcinoma: Taken together, these results point to the possibility that immunodetection of the 85–90 kDa palladin isoform in samples collected by EUS-guided fine-needle aspiration may have diagnostic utility as an early, specific marker for the development of pancreatic adenocarcinoma, which may provide new avenues for diagnosing pancreatic cancer at a treatable stage of the disease.